Advertisement
U.S. markets open in 4 hours 3 minutes
  • S&P Futures

    5,303.25
    -5.00 (-0.09%)
     
  • Dow Futures

    40,136.00
    -8.00 (-0.02%)
     
  • Nasdaq Futures

    18,475.50
    -28.25 (-0.15%)
     
  • Russell 2000 Futures

    2,133.70
    -4.70 (-0.22%)
     
  • Crude Oil

    81.55
    +0.20 (+0.25%)
     
  • Gold

    2,215.40
    +2.70 (+0.12%)
     
  • Silver

    24.54
    -0.21 (-0.86%)
     
  • EUR/USD

    1.0783
    -0.0047 (-0.43%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • dólar/libra

    1.2590
    -0.0048 (-0.38%)
     
  • USD/JPY

    151.4430
    +0.1970 (+0.13%)
     
  • Bitcoin USD

    70,671.58
    +894.92 (+1.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,959.85
    +27.87 (+0.35%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics

Bristol Myers Squibb (BMY) reported $11.41 billion in revenue for the quarter ended December 2022, representing a year-over-year decline of 4.8%. EPS of $1.82 for the same period compares to $1.83 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $11.14 billion, representing a surprise of +2.37%. The company delivered an EPS surprise of +6.43%, with the consensus EPS estimate being $1.71.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Bristol Myers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Sales - Empliciti - U.S: $44 million compared to the $48.52 million average estimate based on three analysts. The reported number represents a change of -12% year over year.

  • Net Sales-Opdivo- U.S: $1.27 billion versus $1.29 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13% change.

  • Net sales- Inrebic- U.S: $17 million versus $20.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Net sales- Inrebic- Non-U.S: $6 million versus $4.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +100% change.

  • Net Sales - Empliciti: $71 million compared to the $75.85 million average estimate based on four analysts. The reported number represents a change of -12.4% year over year.

  • Net Sales-Opdivo: $2.22 billion versus $2.19 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.5% change.

  • Net sales- Pomalyst/Imnovid: $877 million versus the four-analyst average estimate of $926.04 million. The reported number represents a year-over-year change of +2.7%.

  • Net sales- Abraxane: $179 million versus the four-analyst average estimate of $109.47 million. The reported number represents a year-over-year change of -41.3%.

  • Net sales- Inrebic: $23 million versus $23.93 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15% change.

  • Net sales- Reblozyl: $199 million versus $205.74 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +31.8% change.

  • Net sales- Zeposia: $79 million versus the four-analyst average estimate of $84.44 million. The reported number represents a year-over-year change of +64.6%.

  • Net sales- Onureg: $37 million versus $43.68 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +48% change.

View all Key Company Metrics for Bristol Myers here>>>

Shares of Bristol Myers have returned -1.9% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement